Bristol Myers Squibb expands its Nvidia AI factory partnership, reporting 55% cost savings on drug discovery workloads. Here's what it means for investors.

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

Bristol Myers Squibb is the third drugmaker in nine months to announce it is building the largest AI supercomputer in the life sciences industry.